- Market Size (2026)
- USD 553.9 Mn
- Forecast (2036)
- USD 964.2 Mn
- CAGR (2026 to 2036)
- 5.7%
How big is Pharmaceutical Grade Sodium Chloride Market in 2026?
Drug-grade salt sales post a 5.7% CAGR for 2026 to 2036. The market moves from USD 524.0 million in 2025 to an estimated USD 553.9 million in 2026 and a projected USD 964.2 million in 2036.
Adoption of pharmaceutical grade sodium chloride is rising with hospital buying of saline and dialysis fluids. Market size stood at USD 524.0 million in 2025 and is estimated at USD 553.9 million in 2026. The updated FMI report shows that sales are projected to reach USD 964.2 million by 2036, at a 5.7% CAGR from 2026 to 2036. Injection lines are the most intense users of drug-grade salt. Injections take 39% of 2026 application sales, and every saline bag or vial needs certified salt in each unit. In December 2025, an FDA shortage entry showed Hospira discontinuing Sodium Chloride 0.9% Injection in three ADD-Vantage container sizes.[1] Hospitals that used those containers will source saline bags from other IV makers, and each extra bag needs certified injection-grade salt.
Rising certification costs are squeezing margins on certified grades in price-sensitive segments. Producers are therefore focusing on hospital tenders in China, the fastest profiled country at a 6.3% CAGR from 2026 to 2036. Hospital pharmacies preparing feeding bags add a second stream of demand for injection-grade salt, and the parenteral nutrition market carries a 6.5% CAGR from 2026 to 2036. Drug makers qualify lactose and salt under the same pharmacopoeial checks, and the pharmaceutical lactose market is set for a 5.5% CAGR from 2026 to 2036, so excipient distributors will offer both inputs through one supplier audit. The ≥99.9% low-endotoxin crystal already takes 48% of 2026 purity sales, and producers certified for that grade are redefining the boundaries of growth in hospital tenders.
Key Market Trends & Insights
- API-NaCl claimed 85% of 2026 type sales, which FMI links to one grade serving injections, oral salts, osmotic agents and lab reagents.
- Saline bag and vial lines make injections the top application at 39% of 2026 sales. The FDA still listed Dextrose 5% Injection as in shortage in October 2026.[2]
- Demand for the ≥99.9% low-endotoxin crystalline form reached 48% of 2026 purity and form sales, as one high-purity crystal suits many dosage forms.
Regional Highlights
- Hospital procurement and dialysis care put China at the top of the country table, with analysts at FMI seeing a 6.3% CAGR from 2026 to 2036.
- Spain follows at 4.2%, and the USA (3.2%), Germany (3%), South Korea (2.7%) and Japan (2.6%) grow on replacement demand.
- A September 2026 plan from Fresenius Medical Care set out an exit from the China peritoneal dialysis business, with focus on in-center dialysis and critical care.[3]
Market Size & Forecast
Table 1: Market Size and Forecast for the Pharmaceutical Grade Sodium Chloride Market (USD million and percentage), 2025 to 2036
| Metric | Value |
|---|---|
| 2025 Market Size | USD 524.0 million |
| Estimated Market Size in 2026 | USD 553.9 million |
| Projected Market Size by 2036 | USD 964.2 million |
| CAGR, 2026 to 2036 | 5.7% |
| Added Revenue, 2026 to 2036 | USD 410.3 million |
| Market Expansion Multiple | 1.7x |
Hospital procurement in China drives volume growth, FMI’s analysis shows, and US and German buyers keep demand steady through IV and dialysis replacement orders. Hospital and dialysis buyers in China, growing at 6.3%, are the fastest source of the USD 410.3 million gain to 2036. Bulk salt producers serve many industrial uses, and only purified, certified lots move into the pharmaceutical grade. Growth of the wider sodium chloride market reaches injection-grade buyers only through plants holding these approvals.
Supply Security for Injection and Dialysis Grades
Hospital buyers are checking salt suppliers for supply security after IV fluid shortages in 2025 and 2026. The FDA shortage database listed Dextrose 5% Injection as currently in shortage in October 2026.[2] Baxter marked a 1,000 mL dextrose bag unavailable, with estimated recovery in November 2026 and demand increase as the reason.[2] B. Braun, Fresenius Kabi and Otsuka ICU Medical showed the listed presentations as available.[2] IV fluid makers that run short will order more API-grade salt and sugar once lines restart. Dialysis buyers show a different pattern, with U.S. same market treatment growth of -0.9% at Fresenius Medical Care in Q2 2026.[4] The company treated 289,610 patients in 3,513 dialysis clinics as of 30 June 2026.[4] Flat U.S. treatment counts will keep HD-NaCl orders close to replacement levels. K+S reported pharma revenue of €9.6 million in Q2 2026, down from €11.7 million in Q2 2025.[5] Lower K+S pharma revenue and a -0.9% US dialysis treatment trend leave European salt producers chasing export tenders for certified grades.
Table 2: Supply and Buyer Indicators for the Pharmaceutical Grade Sodium Chloride Market (units, patients, EUR and dates), 2025 to 2026
| Indicator | Data Point | Relevance | Source |
|---|---|---|---|
| Hospira Sodium Chloride 0.9% Injection, ADD-Vantage 50, 100 and 250 mL | Discontinuation posted 3 December 2025 | Fewer injection presentations from one maker. | [1] |
| Dextrose 5% Injection status, October 2026 | Currently in shortage | IV fluid lines run tight. | [2] |
| Fresenius Medical Care patients treated, 30 June 2026 | 289,610 in 3,513 clinics | Size of one dialysis buyer. | [4] |
| Fresenius Medical Care U.S. same market treatment growth, Q2 2026 | -0.9% | Flat U.S. dialysis volume. | [4] |
| K+S pharma revenue, Q2 2026 | €9.6 million versus €11.7 million | Softer pharma salt sales at a German producer. | [5] |
| K+S pharma revenue, H1 2026 | €19.5 million versus €22.8 million | Half-year trend for the same producer. | [5] |
| B. Braun Hospital Care growth, 2025 | 6.1% at constant currencies | Hospital product demand in Europe. | [6] |
| Fresenius Medical Care China portfolio actions, Q3 2026 | About €110 million one-time costs | Exit from peritoneal dialysis in China. | [3] |
Analyst Perspective
“Supply concentration in injection-grade salt is the risk I am watching, since one discontinued IV line can shift orders to a few certified producers within months. I expect hospital buyers in the USA and Europe to add second sources, and producers without dual qualification will lose tender volume.”
- Nikhil Kaitwade, Principal Consultant, Future Market Insights.
How is the pharmaceutical grade sodium chloride market segmented?
Type, application, purity and form, and region define the pharmaceutical grade sodium chloride market. API-NaCl holds 85%, injections 39% and the ≥99.9% low-endotoxin crystalline form 48% in 2026.
By type: API-NaCl and HD-NaCl.
By application: injections, hemodialysis, oral rehydration salts, osmotic agents, and other uses such as topical, nasal and lab reagents.
By purity and form: ≥99.9% low-endotoxin crystalline, sterile injectable grade, non-sterile API grade, standard pharma crystalline (≥99.5%), and buffered, modified and specialty forms.
By region: drug-grade salt is tracked in the Americas (North, Latin), Europe (Western, Eastern), the Middle East and Africa, and two Asian blocks, East Asia plus South Asia with the Pacific.
Why does API-NaCl lead type sales?
API-NaCl holds 85% of 2026 type sales, and HD-NaCl holds an estimated 15%.
Table 3: Type Share for the Pharmaceutical Grade Sodium Chloride Market (percentage share), 2026
| Type | Estimated Share (2026) |
|---|---|
| API-NaCl | 85% |
| HD-NaCl | 15% |
| Total | 100.0% |
Table 4: Type Leadership and Market Growth for the Pharmaceutical Grade Sodium Chloride Market (segment and CAGR percentage), 2026 to 2036
| Metric | Value |
|---|---|
| Global CAGR (2026 to 2036) | 5.7% |
| Leading Segment | API-NaCl |
HD-NaCl, a dedicated hemodialysis concentrate grade, holds an estimated 15% of type sales, and many dialysis fluid makers also buy API-NaCl for the same use. API-NaCl reaches injections, oral salts, osmotic agents and lab reagents, and FMI credits API-NaCl with 85% on cost-effectiveness, wide availability and fit with existing procurement standards. U.S. same market treatment growth of -0.9% at Fresenius Medical Care in Q2 2026 keeps HD-NaCl behind.[4] K+S said pharmaceutical-grade salt and potash products are used in dialysis, as active ingredients or excipients in medications and as a carrier medium for vaccines.[7] Pharma accounted for 5% of K+S Industry+ revenues in 2025.[7]
- Local production and sales of the 4008A hemodialysis system in China will end under the Fresenius Medical Care plan.[3]
Why do injections lead application sales?
Injections claim 39% of 2026 application sales, with hemodialysis near 24.6% and oral rehydration salts near 16.3%, both estimated.
Table 5: Application Share for the Pharmaceutical Grade Sodium Chloride Market (percentage share), 2026
| Application | Estimated Share (2026) |
|---|---|
| Injections | 39% |
| Hemodialysis | 24.6% |
| Oral Rehydration Salts | 16.3% |
| Osmotic Agents | 11.2% |
| Others | 8.9% |
| Total | 100.0% |
Every saline bag and vial needs salt in each unit, so injections take 39% of application sales, as FMI estimates. Hemodialysis is second at an estimated 24.6%, held back by treatment counts that move slowly in the USA and Europe. Oral rehydration salts, about 16.3% (estimated), sell at low prices through public health programs, which caps value. Osmotic agents take near 11.2% (estimated) and serve a narrow set of products. Topical, nasal and lab uses make up the other 8.9% (estimated), each bought in small lots. B. Braun reported Hospital Care growth of 6.1% at constant currencies for 2025, the strongest of the three divisions.[6]
- Oral rehydration salts, near 16.3% (estimated), reach buyers through public health and retail channels. Electrolyte drinks meet the same rehydration need at the retail shelf, and growth of the electrolyte drinks market will pull some casual buyers away from sachets.
- B. Braun Avitum, the dialysis division, grew 2.1% at constant currencies in 2025.[6]
Why does the ≥99.9% low-endotoxin crystalline form lead purity and form sales?
The ≥99.9% low-endotoxin crystalline form holds 48% of 2026 purity and form sales, ahead of sterile injectable grade at an estimated 19.2%.
Table 6: Purity and Form Share for the Pharmaceutical Grade Sodium Chloride Market (percentage share), 2026
| Purity and Form | Estimated Share (2026) |
|---|---|
| ≥99.9% Low-Endotoxin Crystalline | 48% |
| Sterile Injectable Grade | 19.2% |
| Non-Sterile API Grade | 14.6% |
| Standard Pharma Crystalline (≥99.5%) | 11.7% |
| Buffered/Modified & Specialty Forms | 6.5% |
| Total | 100.0% |
Procurement teams prefer one high-purity crystal that suits many dosage forms, and the ≥99.9% low-endotoxin crystalline form takes 48% of the purity and form split. Sterile injectable grade holds about 19.2% (estimated), since only parenteral plants need the added sterility step and cost. Non-sterile API grade, at 14.6% (estimated), goes into oral and topical products with lower specification needs. Standard pharma crystalline (≥99.5%) takes an estimated 11.7%, losing tenders to the higher-purity crystal. Buffered, modified and specialty forms are the smallest at near 6.5% (estimated), made in small batches for niche formulations.
What are the drivers, restraints, and opportunities in the pharmaceutical grade sodium chloride market?
Sales of pharmaceutical grade sodium chloride rise with IV fluid shortages on the FDA list, hospital procurement in China and pharmacopoeial tender rules. Certified grades cost more to make, test and ship, so price-sensitive buyers adopt them slowly.
- Driver: Pharmacopoeial and cGMP clauses in hospital salt tenders.
- Restraint: Higher production costs that limit adoption in price-sensitive segments.
- Opportunity: Certified grades for vaccine carriers and home dialysis concentrate.
Certification Mandates Favour Qualified Producers
Hospital and drug-maker buyers write pharmacopoeial and cGMP clauses into salt tenders. Tata Chemicals said in July 2026 that the demand outlook remains positive, supported by premiumization in food, feed, pharma and beverage.[8] Core products such as salt and bicarbonates should deliver stable growth, the company added.[8] Producers with certified plants will take tenders that weigh pharmacopoeial compliance first.
Cost and Supply Complexity Restrain Price-Sensitive Buyers
Certified salt costs more to make, test and ship than industrial grades. Portfolio actions in China will cost Fresenius Medical Care about €110 million in one-time charges, mainly impairment, scrappage and termination costs.[3] Price-sensitive buyers will stay with standard pharma crystalline grades until tender rules change.
Emerging Uses Build the Case for Premium Grades
Specialty forms, osmotic agents and vaccine carriers form the newest uses for pharmaceutical salt. K+S listed use as a carrier medium for vaccines among pharmaceutical applications in the 2025 report.[7] Buffered and specialty forms hold near 6.5% (estimated) and sell in small batches at premium prices. Each hemodialysis machine placed in a home needs HD-NaCl concentrate, so expansion of the dialysis equipment market will add concentrate orders.
Which country CAGRs are profiled in the pharmaceutical grade sodium chloride market?
Table 7: Country CAGR Comparison for the Pharmaceutical Grade Sodium Chloride Market (CAGR percentage), 2026 to 2036
| Country | CAGR (2026 to 2036) |
|---|---|
| China | 6.3% |
| Spain | 4.2% |
| USA | 3.2% |
| Germany | 3% |
| South Korea | 2.7% |
| Japan | 2.6% |
How do country-level CAGRs compare in the pharmaceutical grade sodium chloride market?
Rising chronic kidney disease prevalence and expanding dialysis care support dialysis demand in China, Fresenius Medical Care said in September 2026.[3] The FMI study puts China at a 6.3% CAGR from 2026 to 2036, the highest of the six countries. Spain is second at 4.2%. The USA at 3.2%, Germany at 3%, Japan at 2.6% and South Korea at 2.7% grow below the 5.7% global CAGR on mature replacement demand.
- Fresenius Medical Care is refocusing on in-center dialysis and critical care in China.
- Spain ranks second at 4.2%, below the 5.7% global CAGR.
- Hospira dropped three ADD-Vantage saline sizes in December 2025, so US hospitals are sourcing those bags elsewhere.
- K+S, a German producer, booked lower pharma salt revenue in H1 2026.
- South Korea grows at 2.7% on replacement orders from hospitals and dialysis clinics.
- Japan is the slowest profiled country at 2.6%.
Full report country CAGRs cover: more than 30 countries, with six profiled in depth.
Country-wise Analysis
Spain Pharmaceutical Grade Sodium Chloride Market Outlook (2026 to 2036)
Spain posts a 4.2% CAGR from 2026 to 2036, second among the six countries. Hospital tenders weigh lifecycle cost and sustainability, so producers with documented quality systems will gain Spanish contracts.
Key takeaway: Spain rewards distributors and producers that can meet tender rules on quality and sustainability.
Germany Pharmaceutical Grade Sodium Chloride Market Outlook (2026 to 2036)
K+S, a German producer, reported H1 2026 pharma revenue of €19.5 million, down from €22.8 million.[5] B. Braun grew group sales 5.1% at constant currencies to €9.4 billion in 2025.[6] German sales grow at a 3% CAGR through 2036.
Key takeaway: German hospital demand holds up, and local pharma salt producers will compete on certification depth.
China Pharmaceutical Grade Sodium Chloride Market Outlook (2026 to 2036)
Hospital buying in China drives a 6.3% CAGR through 2036, the top rate of the six profiled countries. In-center dialysis and critical care are now the focus for Fresenius Medical Care in China.[3] In-center dialysis growth will add HD-NaCl volume for local and import suppliers.
Key takeaway: China offers the largest new volume, led by hospital procurement and in-center dialysis.
South Korea Pharmaceutical Grade Sodium Chloride Market Outlook (2026 to 2036)
South Korea posts a 2.7% CAGR from 2026 to 2036, the second-lowest of the six countries. Replacement orders from hospitals and dialysis clinics will make up most Korean volume.
Key takeaway: Korea gives salt producers steady replacement volume at a 2.7% CAGR.
USA Pharmaceutical Grade Sodium Chloride Market Outlook (2026 to 2036)
US sales of drug-grade salt grow at a 3.2% CAGR through 2036. Hospira posted the discontinuation of three ADD-Vantage saline presentations in December 2025.[1] U.S. same market treatment growth at Fresenius Medical Care was -0.9% in Q2 2026.[4] Remaining IV fluid makers will absorb Hospira volume and buy more injection-grade salt.
Key takeaway: Hospira’s exit from three saline sizes will move US injection-grade salt orders to other IV makers.
Japan Pharmaceutical Grade Sodium Chloride Market Outlook (2026 to 2036)
Japan grows at a 2.6% CAGR, the lowest in the country table. Japanese quality rules lengthen supplier qualification, so imported salt will need extended testing before use.
Key takeaway: At 2.6%, Japan will add the least new volume of the six countries.
Who are the notable companies in the pharmaceutical grade sodium chloride market?
K+S Aktiengesellschaft, Nouryon, Tata Chemicals Ltd., Dominion Salt Ltd., Cargill (Salt Business), Salinen Austria AG and Sudsalz GmbH form the major producer group, with Cheetham Salt, Compass Minerals, Swiss Saltworks, Akzo Nobel N.V., Merck KGaA, Spectrum Chemical and Hubei Xingfa Chemicals Group among other suppliers.
FMI groups seven companies as major global players and seven as emerging players or startups. Certified low-endotoxin capacity, the grade behind 48% of 2026 purity sales, is the new battleground for industry leadership, and K+S already lists dialysis, drug and vaccine uses for pharma salt.[7] The emerging group includes chemical suppliers such as Merck KGaA and Spectrum Chemical.
Dated company activity in 2026 came from producers and buyers alike. K+S reported lower pharma revenue for H1 2026.[5] Tata Chemicals reported Q1 FY27 consolidated revenue of Rs 4,255 crore.[8] The China dialysis portfolio of Fresenius Medical Care was refined in September 2026.[3]
- Major global players: K+S Aktiengesellschaft, Nouryon, Tata Chemicals Ltd., Dominion Salt Ltd., Cargill (Salt Business), Salinen Austria AG, and Sudsalz GmbH.
- Emerging players and specialty suppliers: Cheetham Salt, Compass Minerals, Swiss Saltworks, Akzo Nobel N.V., Merck KGaA, Spectrum Chemical, and Hubei Xingfa Chemicals Group.
Competitive Benchmarking: Pharmaceutical Grade Sodium Chloride Market
Table 8: Competitive Benchmarking for the Pharmaceutical Grade Sodium Chloride Market (qualitative documentation ratings), 2026
| Company | Pharma Grade Range | Certification Record | Geographic Reach | Dated Disclosure |
|---|---|---|---|---|
| K+S Aktiengesellschaft | High | High | High | High |
| Tata Chemicals Ltd. | Medium | Medium | High | High |
| Nouryon | Medium | Medium | High | Low |
| Merck KGaA | Medium | High | High | Low |
| Salinen Austria AG | Medium | Medium | Medium | Low |
Each column rating (High, Medium or Low) follows the volume of dated company material.
Key Developments in the Pharmaceutical Grade Sodium Chloride Market
- In September 2026, Fresenius Medical Care set out an exit from peritoneal dialysis in China, with focus on in-center dialysis and critical care.[3]
- In August 2026, K+S reported Q2 2026 pharma revenue of €9.6 million.[5]
- In August 2026, Fresenius Medical Care reported 289,610 patients treated in 3,513 clinics.[4]
- In July 2026, Tata Chemicals said demand for core salt and bicarbonate products should deliver stable growth.[8]
- In March 2026, B. Braun reported 2025 group sales of €9.4 billion.[6]
- In March 2026, K+S reported that pharma made up 5% of Industry+ revenues in 2025.[7]
- In December 2025, the FDA posted Hospira discontinuations of Sodium Chloride 0.9% Injection in ADD-Vantage containers.[1]
Key Players in the Pharmaceutical Grade Sodium Chloride Market
Major Global Players
- K+S Aktiengesellschaft
- Nouryon
- Tata Chemicals Ltd.
- Dominion Salt Ltd.
- Cargill (Salt Business)
- Salinen Austria AG
- Sudsalz GmbH
Emerging Players and Specialty Suppliers
- Cheetham Salt
- Compass Minerals
- Swiss Saltworks
- Akzo Nobel N.V.
- Merck KGaA
- Spectrum Chemical
- Hubei Xingfa Chemicals Group
Pharmaceutical Grade Sodium Chloride Market - Report Scope
Table 9: Report Scope for the Pharmaceutical Grade Sodium Chloride Market (coverage fields and definitions), 2026 to 2036
| Coverage field | Report scope |
|---|---|
| Market breakdown | Type; application; purity and form; region |
| Quantitative units | USD million |
| Market definition | Pharmaceutical grade sodium chloride as API-NaCl and HD-NaCl for injections, hemodialysis, oral rehydration salts, osmotic agents and other uses, in crystalline, sterile, non-sterile and specialty forms. |
| Regions covered | North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa |
| Countries covered | China; Spain; USA; Germany; South Korea; Japan |
| Key companies profiled | K+S Aktiengesellschaft, Nouryon, Tata Chemicals Ltd., Dominion Salt Ltd., Cargill (Salt Business), Salinen Austria AG, Sudsalz GmbH, Cheetham Salt, Compass Minerals, Swiss Saltworks, Akzo Nobel N.V., Merck KGaA, Spectrum Chemical, Hubei Xingfa Chemicals Group |
| Forecast period | 2026 to 2036 |
Pharmaceutical Grade Sodium Chloride Market - Research Methodology
Table 10: Research Methodology for the Pharmaceutical Grade Sodium Chloride Market (research methods and approach), 2026 edition
| Method | Approach |
|---|---|
| Data Sources | Producer reports, hospital and dialysis company results and FDA shortage database entries dated May 2025 or later. |
| Desk Research | Desk research covers IV fluid supply, dialysis volumes, pharma salt revenue and certification trends. |
| Market Sizing and Forecasting | Sizing starts from the 2025 base of USD 524.0 million and the 5.7% CAGR. |
| Data Validation | Shortage entries were matched to the presentation and company named in each FDA record. |
Pharmaceutical Grade Sodium Chloride Market by Segments
Pharmaceutical Grade Sodium Chloride Market segmented by Type:
- API-NaCl
- HD-NaCl
Pharmaceutical Grade Sodium Chloride Market segmented by Application:
- Injections
- Hemodialysis
- Oral Rehydration Salts
- Osmotic Agents
- Others
Pharmaceutical Grade Sodium Chloride Market segmented by Purity and Form:
- ≥99.9% Low-Endotoxin Crystalline
- Sterile Injectable Grade
- Non-Sterile API Grade
- Standard Pharma Crystalline (≥99.5%)
- Buffered/Modified & Specialty Forms
Pharmaceutical Grade Sodium Chloride Market by Region
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East and Africa
Research Sources and Bibliography
- [1] U.S. Food and Drug Administration. (2025, December 3). Drug Shortages database, Sodium Chloride 0.9% Injection, discontinuation entry for Hospira, Inc. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Chloride%200.9per%20Injection&st=d&tab=tabs-2
- [2] U.S. Food and Drug Administration. (2026, October 2). Drug Shortages database, Dextrose Monohydrate 5% Injection. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%20Monohydrate%205per%20Injection&st=c&tab=tabs-1
- [3] Fresenius Medical Care. (2026, September 25). Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership. https://freseniusmedicalcare.com/en/media/newsroom/fresenius-medical-care-refines-china-commercial-strategy-with-focus-on-long-term-growth-and-market-leadership/
- [4] Fresenius Medical Care. (2026, August 3). Q2 2026 Press Release. https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Press_Release.pdf
- [5] K+S Aktiengesellschaft. (2026, August 11). Half-Year Financial Report H1/2026. https://www.kpluss.com/.downloads/ir/2026/halbjahresfinanzbericht-h1-2026/kpluss-half-year-financial-report-h1-2026.pdf
- [6] B. Braun SE. (2026, March 26). Fiscal year 2025: B. Braun meets targets and drives innovation. https://www.bbraun.com/en/about-us/media/press-releases/fiscal-year-2025-b-braun-meets-targets-and-drives-innovation.html
- [7] K+S Aktiengesellschaft. (2026, March 12). K+S 2025 Annual Report. https://www.kpluss.com/.downloads/ir/2025/quartalsmitteilung-q4-2025/kpluss-annual-report-2025.pdf
- [8] Tata Chemicals Ltd. (2026, July 27). Consolidated revenue from operations for the quarter ended 30 June 2026 at Rs 4,255 Cr and EBITDA at Rs 555 Cr. https://www.tatachemicals.com/media/newsroom/press-releases/consolidated-revenue-from-operations-for-the-quarter-ended-30-june-2026-at-4255-cr-and-ebitda-at-555-cr
This bibliography is provided for reader reference. The full report contains the complete reference list and detailed citations.
This Report Answers
- What will pharmaceutical grade sodium chloride sales total in 2026 and 2036?
- What CAGR will the market record from 2026 to 2036?
- Which type and application will hold the largest shares?
- Which purity and form will buyers prefer?
- Which countries will set the growth agenda?
- Which producers will shape competition through 2036?
Frequently Asked Questions
What is the size of the pharmaceutical grade sodium chloride market in 2026?
Sales of USD 553.9 million are expected in 2026, rising to USD 964.2 million in 2036 as FMI projects.
How fast will pharmaceutical grade sodium chloride sales grow?
Sales will grow on a 5.7% CAGR from 2026 to 2036, adding USD 410.3 million. Hospital tenders in China, the fastest country at 6.3%, and pharmacopoeial tender rules will drive the gain.
Which type will lead in 2026?
API-NaCl will lead with 85% of type sales.
Which application will use the most pharmaceutical salt?
Injections will hold a 39% application share in 2026, ahead of hemodialysis at an estimated 24.6%.
Which country will grow fastest?
Top country growth will belong to China, a 6.3% CAGR by the FMI count, with Spain second on 4.2%.
Who are the main producers?
K+S, Nouryon, Tata Chemicals, Dominion Salt, Cargill, Salinen Austria and Sudsalz will form the major producer group.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Key Takeaways
- Market Size and CAGR
- Top Growth Driver
- Fastest Growing Segment
- Leading Region
- Key Companies
- Emerging Opportunities
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Analyst Perspective (What is happening? Why now? What should investors know?)
- Key Questions Answered
- How large is the market?
- What is the CAGR?
- What are key trends?
- Which region dominates?
- Who are the leaders?
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Expert Input and Fieldwork (Primary Evidence)
- Tooling, Models, and Reference Databases
- Data Engineering and Model Build
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics (Drivers, Restraints, Opportunity, Trends)
- Scenario Forecast (Optimistic, Likely, Conservative)
- Impact Analysis
- AI Impact
- Sustainability Impact
- Regulatory Impact
- Technology Impact
- Consumer / Buyer Analysis
- Purchase Drivers
- Adoption Barriers
- Buyer Journey
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter's Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Global Market Analysis and Forecast, 2021 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis, 2021 to 2036
- Global Market Analysis and Forecast, By Type, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Type, 2026 to 2036
- API-NaCl
- HD-NaCl
- Y-o-Y Growth Trend Analysis By Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Type, 2026 to 2036
- Global Market Analysis and Forecast, By Application, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Application, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Application, 2026 to 2036
- Injections
- Hemodialysis
- Oral Rehydration Salts
- Osmotic Agents
- Others
- Y-o-Y Growth Trend Analysis By Application, 2021 to 2025
- Absolute $ Opportunity Analysis By Application, 2026 to 2036
- Global Market Analysis and Forecast, By Purity and Form, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Purity and Form, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Purity and Form, 2026 to 2036
- ≥99.9% Low-Endotoxin Crystalline
- Sterile Injectable Grade
- Non-Sterile API Grade
- Standard Pharma Crystalline (≥99.5%)
- Buffered/Modified & Specialty Forms
- Y-o-Y Growth Trend Analysis By Purity and Form, 2021 to 2025
- Absolute $ Opportunity Analysis By Purity and Form, 2026 to 2036
- Global Market Analysis and Forecast, By Region, 2021 to 2036
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East and Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis and Forecast, By Country, 2021 to 2036
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- By Type
- By Application
- By Purity and Form
- Market Attractiveness Analysis
- By Country
- By Type
- By Application
- By Purity and Form
- Key Takeaways
- Latin America Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- By Type
- By Application
- By Purity and Form
- Market Attractiveness Analysis
- By Country
- By Type
- By Application
- By Purity and Form
- Key Takeaways
- Western Europe Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- By Type
- By Application
- By Purity and Form
- Market Attractiveness Analysis
- By Country
- By Type
- By Application
- By Purity and Form
- Key Takeaways
- Eastern Europe Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- By Type
- By Application
- By Purity and Form
- Market Attractiveness Analysis
- By Country
- By Type
- By Application
- By Purity and Form
- Key Takeaways
- East Asia Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- By Type
- By Application
- By Purity and Form
- Market Attractiveness Analysis
- By Country
- By Type
- By Application
- By Purity and Form
- Key Takeaways
- South Asia and Pacific Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- By Type
- By Application
- By Purity and Form
- Market Attractiveness Analysis
- By Country
- By Type
- By Application
- By Purity and Form
- Key Takeaways
- Middle East and Africa Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- By Type
- By Application
- By Purity and Form
- Market Attractiveness Analysis
- By Country
- By Type
- By Application
- By Purity and Form
- Key Takeaways
- Key Countries Market Analysis
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Type
- By Application
- By Purity and Form
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Type
- By Application
- By Purity and Form
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Type
- By Application
- By Purity and Form
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Type
- By Application
- By Purity and Form
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Type
- By Application
- By Purity and Form
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Type
- By Application
- By Purity and Form
- China
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Type
- By Application
- By Purity and Form
- Emerging Startups
- Innovation Benchmarking
- Competition Analysis
- Competition Deep Dive
- K+S Aktiengesellschaft
- Overview
- Product Portfolio
- Profitability by Market Segments
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Tata Chemicals Ltd.
- Nouryon
- Merck KGaA
- Salinen Austria AG
- Dominion Salt Ltd.
- Cargill (Salt Business)
- Sudsalz GmbH
- Cheetham Salt
- Compass Minerals
- Swiss Saltworks
- Akzo Nobel N.V.
- Spectrum Chemical
- Hubei Xingfa Chemicals Group
- K+S Aktiengesellschaft
- Case Studies
- Success Stories
- Recent Developments
- Competition Deep Dive
- Assumptions & Acronyms Used
